Champions Oncology Launches Radiopharmaceutical Services Platform, Expands Isotope License, and Screens More Than 30 PDX Models
8.7.2025 15:30:00 EEST | ACCESS Newswire | Press release
Expanded offering delivers integrated radiopharmaceutical studies using clinically relevant isotopes and highly characterized PDX tumor models
HACKENSACK, NJ / ACCESS Newswire / July 8, 2025 / Champions Oncology (NASDAQ:CSBR) a leading translational oncology research organization, today announced the full commercial launch of its radiopharmaceutical services platform. This milestone follows the expansion of the company's radioactive materials license, the completion of the radiochemistry infrastructure, and the successful screening of more than thirty PDX models in collaboration with pharmaceutical and biotech partners.
Champions now offers fully integrated radiopharmaceutical workflows combining in vitro, ex-vivo biodistribution, and therapeutic efficacy studies across a wide range of isotopes. The company's platform is uniquely differentiated by its extensive bank of patient-derived xenograft (PDX) tumor models, enabling drug developers to evaluate radiolabeled agents in clinically relevant systems.
"Radiopharmaceuticals represent one of the most exciting frontiers in precision oncology," said Mike Ritchie, Chief Commercial Officer at Champions Oncology. "By combining advanced radiochemistry infrastructure with the world's most deeply characterized PDX bank, we're helping our clients generate meaningful, translational data that drives confident decision-making earlier in oncology drug development."
Champions updated radioactive materials license now includes support for ten key isotopes: Lu-177, Ac-225, In-111, Cu-67, Y-90, Pb-212, At-211 Tb-161, Cu-64, and Zr-89. These additions enable a wide range of study designs including radioligand therapy (RLT), antibody radionuclide conjugates (ARCs), and theranostic approaches.
"Our goal is to help biopharma partners answer critical questions faster, with data that reflects real tumor biology," continued Mike Ritchie, Chief Commercial Officer at Champions Oncology. "The integration of radionuclide workflows into our PDX platform provides a uniquely powerful preclinical toolset for evaluating biodistribution, tumor targeting, and therapeutic effect."
To learn more about Champions Oncology's radiopharmaceutical capabilities, visit:
https://www.championsoncology.com/radiopharmaceutical
About Champions Oncology
Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.
Media Contact
Gavin Cooper
Vice President, Global Marketing
gcooper@championsoncology.com
518 488 9026
SOURCE: Champions Oncology, Inc.
View the original press release on ACCESS Newswire
Champions Oncology, Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Surmodics Opens Medical Device Coating Capabilities in Ireland10.9.2026 17:00:00 EEST | Press release
The Galway Facility Brings Nearly 50 Years of Coating Expertise, Cleanroom Coating Services and Analytical Testing Closer to Medical Device Manufacturers Across Ireland and Europe BALLINASLOE, COUNTY GALWAY, IRELAND / ACCESS Newswire / September 10, 2026 / Surmodics, Inc. today announced its expanded medical device coating capabilities in Galway, Ireland, expanding access to the company's Performance Coatings and coating services for medical device manufacturers throughout Ireland and Europe. The facility now includes dedicated cleanroom environments designed for medical device coating services and brings Surmodics' nearly 50 years of coating experience closer to one of the world's leading medical technology hubs. "Ireland is home to a significant concentration of medical device manufacturers and technology innovators, making it an important market for Surmodics and our customers," said Damien Kilcommons, Vice President of Site Operation at the Ireland facility. "By establishing dedica
MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 202610.9.2026 16:20:00 EEST | Press release
New modular approach will bring together MicroVision lidar hardware, perception software and open sensor integration to enable flexible perception solutions across applications REDMOND, WA AND HANOVER, GER / ACCESS Newswire / September 10, 2026 / MicroVision, Inc. (NASDAQ:MVIS), a leader in advanced perception technologies, today announced plans to unveil its MicroVision Perception Platform™ at IAA Transportation 2026 in Hanover, Germany next week, marking the next evolution of the company's Lidar 2.0 strategy. The new modular platform is designed to bring together MicroVision's expanding portfolio of lidar hardware, perception software and open sensor integration into a flexible architecture that can be configured around the requirements of individual applications spanning automotive, commercial vehicles, industrial, security, defense and aerial use cases. Rather than relying on a fixed sensor configuration or closed "black box" solution, the MicroVision Perception Platform is being d
GA-ASI Unveils Wildfire UAS for Military, Civil and Commercial Roles10.9.2026 16:00:00 EEST | Press release
New Uncrewed Aircraft Combines Exceptional Endurance and Range with Unsurpassed Payload and Affordability at Scale SAN DIEGO, CA / ACCESS Newswire / September 10, 2026 / The world leader in Uncrewed Aircraft Systems, General Atomics Aeronautical Systems, Inc. (GA-ASI) is pleased to announce its groundbreaking Wildfire UAS, a clean-sheet aircraft designed to maximize future investments in large uncrewed aircraft that incorporates lessons learned over decades of large-scale global UAS operations. Wildfire draws upon more than 30 years of delivering more than 1,600 world-changing uncrewed aircraft, including the MQ-1B Predator®, MQ-9A Reaper®, MQ-9B SkyGuardian®, MQ-20 Avenger® and FQ-42A Collaborative Combat Aircraft. GA-ASI aircraft have amassed nearly 10 million total flight hours, mostly in combat, and introduced many of the technologies and concepts now emulated by others around the world. "This is exactly the right design for high-demand missions and cost-conscious customers," said
Steelcase Names Proven Growth Leader Irene Tasi as President9.9.2026 22:00:00 EEST | Press release
Experienced commercial and innovative leader will guide the Steelcase business as the company builds on its design leadership, dealer network and customer-focused strategy. GRAND RAPIDS, MI / ACCESS Newswire / September 9, 2026 / Steelcase today announced Irene Tasi has been named president of Steelcase and will lead the business effective September 14, 2026. Tasi brings more than 25 years of executive leadership experience with a track record leading complex businesses through growth, portfolio development, commercial execution, and organizational change. Her background includes full P&L responsibility, enterprise strategy, innovation, and sales and channel leadership. She will report to Jeff Lorenger, Chairman, President and Chief Executive Officer, HNI Corporation. "Irene brings a combination of commercial leadership, product innovation, operating discipline, and customer focus that makes her exceptionally well-suited to lead Steelcase," said Lorenger. "She has led businesses where
Global Study: Nursing Shortages Require Workforce Policy Solutions, Not Recruitment Campaigns Alone9.9.2026 16:01:00 EEST | Press release
Why people choose nursing, and why they leave, comes down to the same factors PHILADELPHIA, PA / ACCESS Newswire / September 9, 2026 / The global nursing shortage cannot be solved simply by encouraging more people to enter the profession, according to a new evidence brief from the Global Nursing Workforce Centre (GNWC), a joint initiative of the International Council of Nurses (ICN) and TruMerit®. Drawing on research from 42 countries, the brief, The Attractiveness of Nursing for Prospective and Current Nursing Students, finds that the factors influencing people to choose nursing are often the same ones that determine whether they stay. Working conditions, compensation, professional respect, career development opportunities, workplace experiences, and the ability to provide quality care all shape nursing attractiveness to current nurses as well as potential recruits. The findings suggest that countries seeking to strengthen their nursing workforce must focus not only on recruitment, bu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom